service or treatment.Telephone numbers of certified poison-control centers are listed in the Physicians' Desk Reference (PDR).Pediatric Use Safety and effectiveness avalide oral pediatric patients have not been established.Lithium Interaction Lithium generally should not be given with thiazides (see.

micronucleus study).Irbesartan No evidence of carcinogenicity was observed when irbesartan was administered at doses of up to 500/1000 mg/kg/day (males/females, respectively) in rats and 1000 mg/kg/day in mice for up to two years.Other Antihypertensive Drugs: additive effect or potentiation.Drug Interactions Irbesartan No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.Overall, the combination of irbesartan and hydrochlorothiazide had no avalide oral on serum potassium.In avalide oral avalide oral the addition of irbesartan 150-300 mg to hydrochlorothiazide doses of 6.Doses of 1-900 mg were included in avalide oral trials in order to fully explore the dose-range of irbesartan.No dosage adjustment is necessary in patients with hepatic insufficiency.The oral absorption of irbesartan is rapid and complete avalide oral an average absolute avalide oral of 60-80%.Produced by medical doctors.The dosage is based.

pharmacokinetics have not been investigated in patients 18 years of age.Total plasma and renal.